223 related articles for article (PubMed ID: 31189116)
1. Tumor Heterogeneity Underlies Differential Cisplatin Sensitivity in Mouse Models of Small-Cell Lung Cancer.
Böttger F; Semenova EA; Song JY; Ferone G; van der Vliet J; Cozijnsen M; Bhaskaran R; Bombardelli L; Piersma SR; Pham TV; Jimenez CR; Berns A
Cell Rep; 2019 Jun; 27(11):3345-3358.e4. PubMed ID: 31189116
[TBL] [Abstract][Full Text] [Related]
2. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
[TBL] [Abstract][Full Text] [Related]
3. Small cell lung cancer: defining a role for emerging platinum drugs.
Schiller JH
Oncology; 2002; 63(2):105-14. PubMed ID: 12239444
[TBL] [Abstract][Full Text] [Related]
4. The modifier subunit of glutamate cysteine ligase relates to cisplatin resistance in human small cell lung cancer xenografts in vivo.
Nishi M; Abe Y; Fujimori S; Hamamoto A; Inoue Y; Miyazaki N; Oida Y; Ikoma N; Ohnishi Y; Yamazaki H; Ueyama Y; Nakamura M
Oncol Rep; 2005 Aug; 14(2):421-4. PubMed ID: 16012725
[TBL] [Abstract][Full Text] [Related]
5. Reduced expression of Bax in small cell lung cancer cells is not sufficient to induce cisplatin-resistance.
Biagosch J; Huber RM; Bergner A
Eur J Med Res; 2010 Oct; 15(10):448-51. PubMed ID: 21156403
[TBL] [Abstract][Full Text] [Related]
6. Similar chromosomal changes in cisplatin and oxaliplatin-resistant sublines of the H69 SCLC cell line are not associated with platinum resistance.
Stordal B; Peters G; Davey R
Genes Chromosomes Cancer; 2006 Dec; 45(12):1094-105. PubMed ID: 16967470
[TBL] [Abstract][Full Text] [Related]
7. Enhanced sensitivity of small cell lung cancer cell lines to cisplatin and etoposide after infection with adeno-associated virus type 2.
Hillgenberg M; Schlehofer JR; von Knebel Doeberitz M; Klein-Bauernschmitt P
Eur J Cancer; 1999 Jan; 35(1):106-10. PubMed ID: 10211097
[TBL] [Abstract][Full Text] [Related]
8. In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.
Jensen PB; Holm B; Sorensen M; Christensen IJ; Sehested M
Br J Cancer; 1997; 75(6):869-77. PubMed ID: 9062409
[TBL] [Abstract][Full Text] [Related]
9. A Model of the Development of Cisplatin Resistance in Human Small Cell Lung Cancer Xenografts.
Caffrey PB; Frenkel GD; McAndrew KL; Marks K
In Vivo; 2016 11-12; 30(6):745-749. PubMed ID: 27815457
[TBL] [Abstract][Full Text] [Related]
10. Response of a multidrug-resistant human small-cell lung cancer xenograft to chemotherapy.
Arvelo F; Poupon MF; Goguel AF; Lizard G; Bourgeois Y; Arriagada R; Le Chevalier T
J Cancer Res Clin Oncol; 1993; 120(1-2):17-23. PubMed ID: 7903668
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
12. Multidrug-resistant gene expression in small-cell lung cancer.
Savaraj N; Wu CJ; Xu R; Lampidis T; Lai S; Donnelly E; Solomon J; Feun LG
Am J Clin Oncol; 1997 Aug; 20(4):398-403. PubMed ID: 9256898
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of DNA measurements in small cell lung cancer.
Kimura T; Sato T; Onodera K
Cancer; 1993 Dec; 72(11):3216-22. PubMed ID: 8242544
[TBL] [Abstract][Full Text] [Related]
14. Treatment with the Chk1 inhibitor Gö6976 enhances cisplatin cytotoxicity in SCLC cells.
Thompson R; Meuth M; Woll P; Zhu Y; Danson S
Int J Oncol; 2012 Jan; 40(1):194-202. PubMed ID: 21894433
[TBL] [Abstract][Full Text] [Related]
15. The ratio of Bcl-2/Bim as a predictor of cisplatin response provides a rational combination of ABT-263 with cisplatin or radiation in small cell lung cancer.
Li H; Wang H; Deng K; Han W; Hong B; Lin W
Cancer Biomark; 2019; 24(1):51-59. PubMed ID: 30614795
[TBL] [Abstract][Full Text] [Related]
16. In vivo screening models of cisplatin-resistant human lung cancer cell lines using SCID mice.
Heike Y; Takahashi M; Ohira T; Arioka H; Funayama Y; Nishio K; Ogasawara H; Saijo N
Cancer Chemother Pharmacol; 1995; 35(3):200-4. PubMed ID: 7805177
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin.
Nagel R; Avelar AT; Aben N; Proost N; van de Ven M; van der Vliet J; Cozijnsen M; de Vries H; Wessels LFA; Berns A
Mol Cancer Ther; 2019 Apr; 18(4):762-770. PubMed ID: 30872379
[TBL] [Abstract][Full Text] [Related]
18. Determinants of differential doxorubicin sensitivity between SCLC and NSCLC.
Singhal SS; Wickramarachchi D; Singhal J; Yadav S; Awasthi YC; Awasthi S
FEBS Lett; 2006 Apr; 580(9):2258-64. PubMed ID: 16579994
[TBL] [Abstract][Full Text] [Related]
19. Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy.
Zeng-Rong N; Paterson J; Alpert L; Tsao MS; Viallet J; Alaoui-Jamali MA
Cancer Res; 1995 Nov; 55(21):4760-4. PubMed ID: 7585500
[TBL] [Abstract][Full Text] [Related]
20. Shp2 confers cisplatin resistance in small cell lung cancer via an AKT-mediated increase in CA916798.
Yang X; Tang C; Luo H; Wang H; Zhou X
Oncotarget; 2017 Apr; 8(14):23664-23674. PubMed ID: 28423588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
